Rein Therapeutics, Inc. (RNTX) income statement
RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.00 (-0.31%)
Close on Nov 18, 2026Market cap $30.65MP/E –Yield 0.00%
Rein Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -139.9%
Financial strength
- Current ratio
- 4.27
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 88.0%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.56
- Dividend yield
- 0.00%
See a number that looks wrong?